Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from BerGenBio ASA ( (BRRGF) ) is now available.
Oncoinvent’s board has granted newly appointed CEO Ramzi Amri 5,430,000 share options under its long-term incentive program, with an exercise price aligned to the recent market price and a seven-year term, subject to a vesting schedule that ties the bulk of the award to continued employment. The board argues that the option package, which will be adjusted to reflect an upcoming reverse share split, is in line with market practice and is intended to strengthen the company’s ability to attract and retain key talent as it advances its radiopharmaceutical pipeline, signaling a commitment to long-term value creation during a critical phase of clinical and commercial development.
More about BerGenBio ASA
Oncoinvent ASA is a clinical-stage biotechnology company specializing in radiopharmaceutical cancer therapies. Its lead product candidate, Radspherin®, is an investigational alpha-emitting radium-224-based treatment designed for local administration into body cavities to target micro-metastatic disease after surgery, particularly in peritoneal carcinomatosis from ovarian and colorectal cancers. The company is running an ongoing randomized Phase 2 trial in the US, UK and Europe following completion of early-stage studies that have shown encouraging efficacy and a favorable safety profile, supported by in-house manufacturing in Oslo and a listing on the Oslo Stock Exchange.
Average Trading Volume: 1,361,358
Current Market Cap: NOK210M
For an in-depth examination of BRRGF stock, go to TipRanks’ Overview page.